The keystone of Taiga Biotechnologies’ proprietary technologies, and the underlying basis for each of the company’s product programs, is Taiga’s platform for the unlimited expansion and purification of undifferentiated hematopoetic stem cells (HSCs) in a laboratory setting.
This technology involves the transduction of primary HSCs with specific genes (or proteins, which are gene products) and their subsequent expansion in culture. The expanded HSCs are fully functional stem cells, as demonstrated by their ability to repopulate bone-marrow depleted mice with functional cells of all hematopoietic lineages. Taiga’s accomplishment marks the first time that long-term repopulating, self-renewing HSCs have been expanded to such an extent. Recent attempts in the field by others have succeeded in expanding a more differentiated, short-term HSC.
